Loading…
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-153M | $-145M | $-123M | -47.4% | -100.0% | - |
| 2024 | $87M | $-255M | $-302M | $-168M | -183.1% | -77.1% | -712.4% |
| 2023 | $381M | $40M | $49M | $11M | 11.4% | 1612.9% | - |
| 2022 | $22M | $-201M | $-198M | $-182M | -58.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 22.23 | 380.79 | 87.37 | 0 |
| Cost Of Revenue | 2.99 | 25.44 | 124.63 | 0 |
| Gross Profit | 19.24 | 355.35 | -37.26 | 0 |
| Operating Expense | 220.58 | 316.54 | 218.41 | 153.29 |
| Operating Income | -201.34 | 38.80 | -255.68 | -153.29 |
| EBITDA | -200.85 | 39.89 | -254.77 | -152.77 |
| EBIT | -201.34 | 38.80 | -255.68 | -153.29 |
| Pretax Income | -197.60 | 54.30 | -302.14 | -144.69 |
| Tax Provision | 0.77 | 5.03 | -0.39 | 0.05 |
| Net Income | -198.38 | 49.27 | -301.74 | -144.74 |
| Net Income Common Stockholders | -198.38 | 49.27 | -301.74 | -144.74 |
| Total Expenses | 223.57 | 341.98 | 343.05 | 153.29 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Interest Income | 4.29 | 16.16 | 13.81 | 9.30 |
| Research And Development | 93.45 | 128.19 | 104.08 | 90.40 |
| Selling General And Administration | 127.13 | 188.36 | 114.33 | 62.89 |
| Normalized EBITDA | -200.85 | 39.89 | -195.72 | -152.77 |
| Normalized Income | -198.38 | 49.27 | -242.75 | -144.74 |
| Basic EPS | -3.39 | 0.73 | -4.43 | 0 |
| Diluted EPS | -3.39 | 0.70 | -4.43 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | -0.06 | 0 |
| Tax Rate For Calcs | 0.21 | 0.09 | 0 | 0 |
| Total Unusual Items | 0 | 0 | -59.05 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | -59.05 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -198.38 | 49.27 | -301.74 | -144.74 |
| Reconciled Depreciation | 0.49 | 1.09 | 0.90 | 0.53 |
| Reconciled Cost Of Revenue | 2.99 | 25.44 | 124.63 | 0 |
| Net Interest Income | 4.29 | 16.16 | 13.81 | 9.30 |
| Net Income From Continuing And Discontinued Operation | -198.38 | 49.27 | -301.74 | -144.74 |
| Total Operating Income As Reported | -201.34 | 38.80 | -314.73 | -153.29 |
| Diluted Average Shares | 58.50 | 69.99 | 68.14 | 0 |
| Basic Average Shares | 58.50 | 67.23 | 68.14 | 0 |
| Diluted NI Availto Com Stockholders | -198.38 | 49.27 | -301.74 | -144.74 |
| Net Income Including Noncontrolling Interests | -198.38 | 49.27 | -301.74 | -144.74 |
| Net Income Continuous Operations | -198.38 | 49.27 | -301.74 | -144.74 |
| Other Income Expense | -0.55 | -0.66 | -60.27 | -0.70 |
| Other Non Operating Income Expenses | -0.55 | -0.66 | -1.21 | -0.70 |
| Special Income Charges | 0 | 0 | -59.05 | 0 |
| Other Special Charges | 0 | 0 | 36.20 | 0 |
| Restructuring And Mergern Acquisition | 0 | 0 | 22.85 | 0 |
| Net Non Operating Interest Income Expense | 4.29 | 16.16 | 13.81 | 9.30 |
| Interest Expense Non Operating | 0 | 0 | 0 | 0 |
| Interest Income Non Operating | 4.29 | 16.16 | 13.81 | 9.30 |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| General And Administrative Expense | 0 | 0 | 0 | 0 |
| Other Gand A | 0 | 0 | 0 | 0 |
| Operating Revenue | 27.10 | 431.43 | 87.37 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc.this co. | AMLX | $1.7B | - | 5.62 | -47.4% | -9.25 |
| Taysha Gene Therapies, Inc. | TSHA | $1.8B | - | 7.24 | -44.1% | -14.19 |
| Sonida Senior Living, Inc. | SNDA | $1.8B | - | -37500.00 | -125.8% | 57.41 |
| Harmony Biosciences Holdings, Inc. | HRMY | $1.8B | 11.23 | 2.05 | 18.2% | 4.68 |
| Palvella Therapeutics, Inc. | PVLA |
| $1.8B |
| - |
| 54.18 |
| -149.1% |
| - |
| Recursion Pharmaceuticals, Inc. | RXRX | $1.7B | - | 1.54 | -57.0% | -1.91 |
| Nurix Therapeutics, Inc. | NRIX | $1.7B | - | 3.57 | -49.1% | -4.02 |
| Sionna Therapeutics, Inc. | SION | $1.7B | - | 5.46 | -24.5% | -16.50 |
| Agios Pharmaceuticals, Inc. | AGIO | $1.7B | - | 1.37 | -34.6% | -1.37 |
| Peer Median | - | 11.23 | 2.81 | -46.6% | -1.91 | |